Scholarlink

<p>The genus <i>Chaetomium</i>, Chaetomiaceae, is a promising source of secondary metabolites with proven pharmacological activities. In the present study, a new strain of <i>Chaetomium globosum</i> (KM651986) was investigated resulting in the isolation of two unreported lecanoric acid derivatives <b>1</b> and <b>2</b>, for the first time, which were analyzed using spectroscopic methods, SwissSimilarity, and SwissTargetPrediction. Thus, predicting the possible biological targets for <b>1</b> and <b>2.</b> Consequently, the crude methanol extract of <i>C. globosum</i>, compounds <b>1</b> and <b>2</b> were investigated for their anti-diabetic activity using streptozocin (STZ) - induced diabetic rat model. Results indicated that the crude extract <i>C. globosum</i> and compounds <b>1</b> and <b>2</b>&#xa0;significantly impacted serum glucose, insulin, HbA1c levels, hepatic glucose-6-phosphate dehydrogenase (G6PD) content, cAMP levels, and hepatic α-amylase content. Compound <b>2</b> showed a significant decrease in serum glucose by 40% and an increase in insulin level by 65% compared to STZ-diabetic rats, indicating its potent anti-hyperglycemic effect and potential in improving insulin secretion and cell regeneration. Compound <b>2</b> also elevated hepatic G6PD, normalized cAMP levels, and decreased hepatic α-amylase, indicating its potential in improving glucose metabolism at the hepatic level. Therefore, compound <b>2</b> emerges as particularly promising anti-diabetic candidate meriting further investigation into its potential therapeutic mechanisms of action.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Two unreported lecanoric acid derivatives isolated from Chaetomium globosum KM651986 and their anti-diabetic effect

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Rehab A. Hussein,
  • Enaam M. AbouZeid,
  • Dalia O. Saleh,
  • Gehad A. Abdel Jaleel,
  • Abeer A. Abd El Aty,
  • Hiroyuki Morita,
  • Ahmed A. El-Beih

摘要

The genus Chaetomium, Chaetomiaceae, is a promising source of secondary metabolites with proven pharmacological activities. In the present study, a new strain of Chaetomium globosum (KM651986) was investigated resulting in the isolation of two unreported lecanoric acid derivatives 1 and 2, for the first time, which were analyzed using spectroscopic methods, SwissSimilarity, and SwissTargetPrediction. Thus, predicting the possible biological targets for 1 and 2. Consequently, the crude methanol extract of C. globosum, compounds 1 and 2 were investigated for their anti-diabetic activity using streptozocin (STZ) - induced diabetic rat model. Results indicated that the crude extract C. globosum and compounds 1 and 2 significantly impacted serum glucose, insulin, HbA1c levels, hepatic glucose-6-phosphate dehydrogenase (G6PD) content, cAMP levels, and hepatic α-amylase content. Compound 2 showed a significant decrease in serum glucose by 40% and an increase in insulin level by 65% compared to STZ-diabetic rats, indicating its potent anti-hyperglycemic effect and potential in improving insulin secretion and cell regeneration. Compound 2 also elevated hepatic G6PD, normalized cAMP levels, and decreased hepatic α-amylase, indicating its potential in improving glucose metabolism at the hepatic level. Therefore, compound 2 emerges as particularly promising anti-diabetic candidate meriting further investigation into its potential therapeutic mechanisms of action.